ArticleJournal of translational medicine2026
Micheliolide suppresses epithelial-mesenchymal transition of lens epithelial cells via downregulating matrix metalloproteinase 8 to ameliorate posterior capsular opacification.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePosterior capsular opacification (PCO) is a significant complication that causes decreased vision in cataract patients after surgery. Epithelial-mesenchymal transition (EMT) and inflammation are key factors in PCO development. This study examined the protective effect of Micheliolide (MCL) in preventing PCO and its related mechanisms.
methodsIn vivo studies were conducted using an extracapsular lens extraction (ECLE) model combined with intracameral injection, while in vitro experiments utilized TGF-β2-induced EMT in lens epithelial cells (LECs). In vivo biological effects were assessed by TUNEL staining and alizarin red staining. The expression levels of EMT and inflammatory markers were analyzed by Western blotting, quantitative real-time PCR (qRT-PCR), and immunofluorescence. Hematoxylin-eosin (HE) staining, Transwell assays, and scratch wound healing assays were employed to evaluate the migratory and proliferative capacities of LECs.
resultsIn both in vivo and in vitro experiments, MCL treatment significantly suppressed the inflammatory response, expression of EMT markers, and the proliferative and migratory capacities of LECs. To further elucidate the underlying mechanism, RNA sequencing was performed on capsular bags collected at 0 h, 24 h, and 5d post-ECLE. Transcriptomic analysis revealed that matrix metalloproteinase 8 (MMP8) was upregulated at 24 hours after surgery, and this induction was markedly attenuated by MCL administration. Consistent with these findings, in vitro studies demonstrated that combining MCL with an MMP8 inhibitor (M8I) synergistically suppressed the expression of EMT-related proteins in LECs.
conclusionOur research confirms the effectiveness of MCL in inhibiting PCO through anti-inflammatory and anti-fibrotic effects, and it exerts its mechanism of inhibiting EMT through MMP8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.